

Legends of figures

Figure 1: Flow chart of patients through the study.

Figure 2: Genotype frequencies of *TNFA* gene polymorphisms and HLA DRB1 shared epitope (SE) among subjects with 50% response to ADA therapy according to the American College of Rheumatology (ACR) criteria (ACR50) (responders) and non responders at week 12 after treatment initiation. A. Shared epitope copy numbers (0, 1 or 2). B. Shared epitope carrier status. C. *TNF* -238 A/G genotypes; D. *TNF* -308 A/G genotypes; E. *TNF* -857 C/T genotypes

Figure 3: Haplotype combinations frequencies among ADA ACR50 responders and non responders at week 12. A. Comparison of the four main haplotypes of the *TNF* locus. B. Comparison of the GGC homozygous haplotype with all the other haplotypes. C. Comparison of the GGC homozygous haplotype with all the other haplotypes by treatment with ADA plus methotrexate (MTX), ADA plus any other disease-modifying antirheumatic drug (DMARD) or ADA alone (monotherapy).

Figure 4: Time course of ACR50 response according to treatment and GGC homozygous haplotype carrier status. A. Patients treated with ADA plus methotrexate (MTX); B. Patients treated with ADA plus any other disease-modifying antirheumatic drug (DMARD); C. Patients treated with ADA alone; other=other than GGC homozygous haplotype; W=week.

Figure 1




Figure 2





Figure 2 (follow)



E

Figure 3




Figure 4

